Company profile
UK company 12479455, incorporated on 24 February 2020.
Nk:Io Ltd is a UK company with status Active founded in 2020 based in London.
Company number 12479455
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
AA | Transaction MzUzMDA5MzMxOWFkaXF6a2N4
Published 02 Jul 2026 15:02
Last confirmation statement made up date
Last accounts made up date
AD01 | Transaction MzM5MjMyODYzMGFkaXF6a2N4
Published 13 Aug 2026 13:42
AD01 | Transaction MzM0Njc1OTU1N2FkaXF6a2N4
Published 13 Aug 2026 13:42
Company registered at Companies House
NK:IO develops new immunotherapeutic approaches, leveraging the power of natural killer cells.
Exploiting our pioneering discoveries in small molecule and peptide ligand activation of blood stem cell progenitors, NK:IO's platform technologies offer the potential for greatly enhanced NK cell expansion and tumour killing capacity in the field of NK cell-based therapy for cancer. wNK:IO Cells Using umbilical cord blood as a source of blood stem cells, we have produced first-generation wNK:IO human NK cells for cancer immunotherapy. The synergistic combination of a small molecule antagonist and recombinant protein ligand provides the basis for dramatically enhanced NK cell expansion for use as a cell therapy. The wNK:IO cells generated are highly functional and do not exhibit the 'exhaustion' phenotype that limits the efficacy of competitor NK cell technologies. eNK:IO Cells While our enhanced expansion methodology will allow us to improve and expand the use of NK cell therapies, it is likely, for certain hard to treat cancer subtypes, that cell engineering will be required to increase the therapeutic effect. Our next generation engineered eNK:IO human NK cells have been produced by deleting relevant inhibitory receptors on the cell surface prior to differentiation to mature NK cells. These engineered "super" NK cells exhibit enhanced cytotoxic and tumour cell-sensing properties. dNK:IO REV-ERB Antagonists We have leveraged the validated biological mechanism in our NK cell expansion technologies to develop a novel series of small molecules. The dNK:IO platform can be used to significantly mobilise and enhance NK cell production in vivo. This ability to produce large numbers of NK cells on demand represents a highly novel approach, with significant potential implications for the immune system's ability to carry out anti-tumour responses as well as tackle long-term pathogen infection.
